Audio is streamed directly from the publisher (api.substack.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
As I discuss the issues of GLP-1 agonist and GLP-1/GIP co-agonist weight loss drugs Semaglutide (Ozempic/Wegovy) and Tirzepatide (Mounjaro/Zepbound)I’ve been increasingly hearing from people who are engaged in practices with these drugs that are not remotely evidence based.
Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe